Subsidiary of Zhejiang Anglikang Pharmaceutical (002940.SZ) obtained the approval notice for the application for the listing of chemical raw materials.

Zhejiang Anglikang Pharmaceutical (002940.SZ) announced that its subsidiary Hunan Kerui Biopharmaceutical Co., Ltd. (referred to as "Kerui Biopharm") recently received the "Approval Notice for the Marketing Application of Chemical Raw Materials Nonaphenols" (Notification No .: 2025YS00117) from the National Medical Products Administration. Nonaphenols is a type II 5-alpha reductase inhibitor, and its preparations are mainly used in clinical practice for the treatment of benign prostatic hyperplasia (BPH) and male androgenic alopecia. The approval of this variety will further enrich the company's product line and enrich the variety of chemical raw materials.